ARKG is the ARK Genomic Revolution ETF, an actively managed fund that seeks long-term capital growth by investing at least 80% of its assets in companies ARK Invest believes will benefit from the "genomics revolution." Rather than tracking a passive index, the fund is built around a concentrated, high-conviction theme spanning targeted therapeutics, bioinformatics, molecular diagnostics, and synthetic biology.
The portfolio is overwhelmingly healthcare-focused, with roughly 99% of assets in the sector and a modest sliver in information technology. Top holdings have recently included TWST (Twist Bioscience), TXG (10x Genomics), TEM (Tempus AI), CRSP (CRISPR Therapeutics), and NTRA (Natera). Geographically, exposure is dominated by the United States (roughly 80–90%), with the balance in Switzerland and the United Kingdom. The fund carries a 0.75% net expense ratio and leans heavily toward small- and mid-cap equities, many of which are not yet profitable.
This positioning means the ETF's future performance potential is driven less by broad-market beta and more by the pace of technology adoption, clinical success, and the availability of growth capital. When risk appetite is strong, its high-conviction portfolio exposure can magnify returns; when financing tightens, the same concentration amplifies drawdowns.
The macro outlook for ARKG hinges on the interplay between interest rates, inflation, and risk appetite. Genomics and precision-medicine companies are classic long-duration assets: their valuations depend on earnings expected years in the future, making them acutely sensitive to discount rates. A sustained easing cycle would likely support the sector outlook, while persistent inflation or renewed rate pressure would weigh on multiples.
Broader market trends also matter. As an actively managed theme fund with a beta well above the S&P 500, ARKG tends to outperform in risk-on, growth-led markets and lag in defensive or value-driven environments. Within healthcare, secular demand for earlier disease detection, personalized therapy, and cost-efficient drug development underpins a favorable long-term asset-class outlook, but near-term performance is often dictated by financing conditions and sentiment rather than fundamentals alone.
Investors evaluating the future outlook for ARKG can complement fundamental research with technical, AI-driven tools. Tickeron's Trend Prediction Engine is an AI-powered forecasting tool that helps traders identify whether a stock, ETF, or other asset may move bullish, bearish, or sideways over the next week or month. It is designed to help users spot developing trends, evaluate possible breakouts or reversals, and explore predictions across a wide range of tradable instruments. The product includes searchable prediction categories, historical context, and alert-oriented functionality. For those tracking market trends in genomics and beyond, exploring the Trend Prediction Engine can add a forward-looking signal layer to a disciplined research process.
Structurally, ARKG is positioned around several durable, multi-decade themes. The falling cost of DNA sequencing is expanding the addressable market for genomic testing, while CRISPR-based editing is maturing from research tool to clinical therapy. Simultaneously, AI is accelerating drug discovery by turning large biological datasets into trainable models—a trend ARK has explicitly identified as a core investment thesis.
Demographic forces also support the theme: aging populations in developed markets are increasing demand for early detection and targeted treatment of chronic and age-related disease. Over the long run, the winners may be the platform and "picks-and-shovels" companies that enable these innovations, a direction ARK's recent rebalancing activity appears to reflect. However, the same structural trends carry structural risks, including high valuation sensitivity, binary clinical outcomes, and concentration in unprofitable early-stage firms. The long-term outlook is compelling in scope, but it is accompanied by above-average volatility and capital-market dependence.
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
| 1 Day | |||
|---|---|---|---|
| ETFs / NAME | Price $ | Chg $ | Chg % |
| SRTY | 33.09 | 2.56 | +8.39% |
| ProShares UltraPro Short Russell2000 (SRTY) | |||
| FMHI | 45.87 | 0.04 | +0.10% |
| First Trust Municipal High Income ETF (FMHI) | |||
| GLO | 5.06 | -0.14 | -2.69% |
| Clough Global Opportunities Fund | |||
| LBAY | 26.92 | -0.95 | -3.42% |
| Leatherback Long/Short Alternative Yield ETF (LBAY) | |||
| MEGX | 16.09 | -2.96 | -15.53% |
| Corgi U.S. Mega-Cap Growth 2x Daily ETF (MEGX) | |||
| 1 Day | |||
|---|---|---|---|
| ETFs / NAME | Price $ | Chg $ | Chg % |
| MEGX | 16.09 | -2.96 | -15.53% |
| Corgi U.S. Mega-Cap Growth 2x Daily ETF (MEGX) | |||
| LBAY | 26.92 | -0.95 | -3.42% |
| Leatherback Long/Short Alternative Yield ETF (LBAY) | |||
| GLO | 5.06 | -0.14 | -2.69% |
| Clough Global Opportunities Fund | |||
| FMHI | 45.87 | 0.04 | +0.10% |
| First Trust Municipal High Income ETF (FMHI) | |||
| SRTY | 33.09 | 2.56 | +8.39% |
| ProShares UltraPro Short Russell2000 (SRTY) | |||
A.I.dvisor indicates that over the last year, ARKG has been closely correlated with XBI. These tickers have moved in lockstep 77% of the time. This A.I.-generated data suggests there is a high statistical probability that if ARKG jumps, then XBI could also see price increases.
| Ticker / NAME | Correlation To ARKG | 1D Price Change % | ||
|---|---|---|---|---|
| ARKG | 100% | -5.64% | ||
| XBI - ARKG | 77% Closely correlated | -2.73% | ||
| IHI - ARKG | 54% Loosely correlated | -1.16% | ||
| VHT - ARKG | 48% Loosely correlated | -0.40% | ||
| IYH - ARKG | 43% Loosely correlated | -0.32% | ||
| XLV - ARKG | 38% Loosely correlated | -0.12% | ||
More | ||||
ARKG saw its Moving Average Convergence Divergence Histogram (MACD) turn negative on November 04, 2026. This is a bearish signal that suggests the stock could decline going forward. Tickeron's A.I.dvisor looked at 50 instances where the indicator turned negative. In 47 of the 50 cases the stock moved lower in the days that followed. This puts the odds of a downward move at 90%.
The Momentum Indicator moved below the 0 level on November 04, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on ARKG as a result. In 73 of 83 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 88%.
ARKG moved below its 50-day moving average on November 02, 2026 date and that indicates a change from an upward trend to a downward trend.
The 10-day moving average for ARKG crossed bearishly below the 50-day moving average on November 10, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 22 of 22 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 90%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where ARKG declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 90%.
ARKG broke above its upper Bollinger Band on October 27, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
The Aroon Indicator for ARKG entered a downward trend on November 10, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
The RSI Indicator entered the oversold zone -- be on the watch for ARKG's price rising or consolidating in the future. That's also the time to consider buying the stock or exploring call options.
The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 12 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.
Following a +8.13% 3-day Advance, the price is estimated to grow further. Considering data from situations where ARKG advanced for three days, in 249 of 278 cases, the price rose further within the following month. The odds of a continued upward trend are 90%.